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Abstract: MicroRNAs (miRNAs) constitute a class of short noncoding RNAs which regulate gene
expression by targeting messenger RNA, inducing translational repression and messenger RNA
degradation. This regulation of gene expression by miRNAs in adipose tissue (AT) can impact on
the regulation of metabolism and energy homeostasis, particularly considering the different types of
adipocytes which exist in mammals, i.e., white adipocytes (white AT; WAT), brown adipocytes (brown
AT; BAT), and inducible brown adipocytes in WAT (beige or brite or brown-in-white adipocytes).
Indeed, an increasing number of miRNAs has been identified to regulate key signaling pathways
of adipogenesis in BAT, brite AT, and WAT by acting on transcription factors that promote or
inhibit adipocyte differentiation. For example, MiR-328, MiR-378, MiR-30b/c, MiR-455, MiR-32,
and MiR-193b-365 activate brown adipogenesis, whereas MiR-34a, MiR-133, MiR-155, and MiR-27b
are brown adipogenesis inhibitors. Given that WAT mainly stores energy as lipids, whilst BAT
mainly dissipates energy as heat, clarifying the effects of miRNAs in different types of AT has recently
attracted significant research interest, aiming to also develop novel miRNA-based therapies against
obesity, diabetes, and other obesity-related diseases. Therefore, this review presents an up-to-date
comprehensive overview of the role of key regulatory miRNAs in BAT, brite AT, and WAT.
Keywords: adipose tissue; BAT; WAT; brite; beige; adipocytes; micro-RNA; metabolism; energy
homeostasis; obesity; diabetes
1. Introduction
Adipose tissue (AT) consists of different cell types (e.g., mature adipocytes, pre-adipocytes,
and immune cells) and secretes more than 600 different molecules collectively referred to as adipokines,
functioning as an endocrine organ with pleiotropic functions that regulate whole body metabolism [1–3].
Based on morphology and function, AT has been traditionally categorized into white and brown
subtypes (WAT and BAT, respectively), whilst brite AT (beige or brown-in-white AT) has more
recently attracted research attention due to its potential role in combating obesity and obesity-related
diabetes [4–7].
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AT originates from the mesoderm, where WAT and BAT follow separate differentiating lineages,
which are tightly orchestrated by an array of transcription factors [8,9]. Of note, mesenchymal stem
cells can commit to adipogenic or myogenic lineages that give rise to white or brown adipocytes
or myocytes [10]. As such, BAT and myocytes develop from the myogenic lineage, deriving from
myogenic factor 5 positive cells (MYF5+), whereas WAT has an adipogenic lineage and is MYF5− [11].
1.1. White Adipose Tissue (WAT)
WAT is markedly heterogeneous, consisting mainly of mature adipocytes and the stromal vascular
fraction (SVF) [2]. The latter contains various cell types, including immune cells and pre-adipocytes,
which are the major adipocyte progenitor cells [2]. The primary physiological role of WAT is to
store energy in the form of lipids, with excess free fatty acids (FFA) and glycerol being stored
as triacylglycerols (triglycerides) in adipocytes. When energy is required by other organs/tissues,
these lipids are hydrolyzed and FFA are released back into the circulation [12]. However, it is now
well-established that WAT has multiple metabolic, endocrine and immune functions [13], which regulate
a number of physiological processes (e.g., energy and glucose homeostasis, appetite, reproduction
and vascular functions) through secretion of adipokines [14,15]. Obesity and dysregulation of normal
WAT function can lead to accumulation of lipids in ectopic sites/tissues, promoting the development of
cardio-metabolic diseases [14,15]. Each mature WAT adipocyte has a single, large lipid droplet that
occupies most of the space within the cytoplasm, while the rest of its components (e.g., the nucleus,
mitochondria and endoplasmic reticulum) are pushed towards the sides of the cell [16,17].
Of note, WAT can be divided into two main categories, namely, visceral and subcutaneous
(scAT) with each having distinct functions in health and disease [2]. Visceral AT constitutes a smaller
percentage of the total body fat mass and is found in the intra-abdominal regions (mainly in the
omentum and mesentery), and around major organs, such as the kidneys, liver and heart [18].
Conversely, scAT accounts for most of the total body fat mass and is mainly located in the abdominal
wall and the femoral-gluteal areas [2,16,19]. Based on location, AT can be further categorized into
different depots. For example, in the mouse visceral AT is categorized into peri-gonadal, peri-renal,
triceps-associated and cardiac, while scAT into anterior, inter-scapular and inguinal [2]. The exact range
of functions of each AT depot and their response to different stimuli (e.g., nutritional and hormonal
stimuli) is yet to be fully clarified, including potential differences between species [20].
WAT expansion, dysfunction, and inflammation are hallmarks of obesity and play a critical
role in the development of highly prevalent cardio-metabolic disorders, such as insulin resistance
(IR), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), atherosclerosis,
and cardiovascular disease (CVD) [21]. Indeed, compelling research indicates that accumulation of
excess ectopic and visceral AT are key contributors to the pathophysiology of these obesity-related
cardio-metabolic diseases due to their metabolically deleterious profile/function in obesity [22–24].
1.2. Brown Adipose Tissue (BAT)
BAT is distinctively thermogenic, regulating body temperature by expending energy derived from
lipids to produce heat, whilst it also has an active secretory role by releasing adipokines and factors
with paracrine and/or endocrine actions [25,26]. In mice, BAT is located in five major depots, i.e.,
inter-scapular, mediastinal, peri-renal, axillary, and cervical BAT [8,27]. In humans, until recently BAT
was thought to be functional only in neonates; however, it is now well-documented that adult humans
also have certain BAT depots which can be activated by cold [28–30]. BAT is characterized by having
multi-locular small lipid droplets and a high number of iron containing mitochondria, which account
for its characteristic brown color [25,26]. Uncoupling protein 1 (UCP1) is exclusively expressed
within the inner membrane of the mitochondria of brown adipocytes and uncouples fuel oxidative
phosphorylation from adenosine triphosphate (ATP) synthesis to generate heat, thus playing a key role
in energy dissipation via non-shivering thermogenesis [8,27]. Notably, the thermogenic program of
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BAT is activated not only by cold exposure but also by exercise and other factors, such as adrenergic
stimulation, natriuretic peptides, retinoids, capsinoids, thyroid hormones, and glucocorticoids [31].
Overall, BAT is highly innervated by the sympathetic nervous system (SNS) and so, upon cold
exposure or overfeeding, BAT thermogenesis is stimulated by the release of norepinephrine which
activates the β3 adrenergic receptors expressed on brown adipocyte cell membranes [32]. In turn,
this activation results in stimulation of intercellular cyclic adenosine 3′,5′-monophosphate (cAMP)
synthesis that activates protein kinase cAMP dependent (PKA) signaling [27]. This further stimulates
lipid catabolism (lipolysis of triglycerides) to release FFA that are used as a fuel substrate for UCP1
derived thermogenesis [27]. Due to consuming energy from glucose and lipids for thermogenesis,
BAT is regarded as a potential target for novel interventions against obesity [10,33]. Indeed, BAT activity
increases the whole-body energy expenditure and, hence, may play a protective role against obesity and
obesity-related complications [34–36]. Moreover, BAT activity appears to be impaired in individuals
with obesity and correlates inversely to the body mass index (BMI), body fat content, and central
adiposity [37,38].
1.3. Brite Adipose Tissue (Beige or Brown-in-White Adipose Tissue)
Brite adipocytes are found in WAT depots, where white adipocytes can be converted to brown-like
adipocytes [10]. Brite AT is even more heterogeneous, as it originates from MYF5+ and MYF5−
lineages [4–7,39,40], and shares morphological, molecular, and thermogenic characteristics/functions
with typical BAT. As such, brite AT expresses inducible UCP1 and exhibits a medium density of
mitochondria [4–7]. The plasticity of WAT and brite AT appears to play a significant role [41],
as bidirectional inter-conversion processes have been documented between WAT and brite AT [42].
In addition to expressing adipogenic genes (UCP1; Cell death-inducing DNA fragmentation
factor-like effector A, CIDEA; CCAAT/enhancer-binding protein beta, C/EBPB; and Peroxisome
proliferator-activated receptor gamma coactivator 1alpha, PGC1A), brite adipocytes also express
certain brite markers, such as CD137 (4-1BB, or tumor necrosis factor receptor superfamily member 9,
TNFRSF9), transmembrane protein 26 (TMEM26), or T-Box transcription factor 1 (TBX1) [36,43].
Interestingly, browning of WAT is induced by cold exposure or genetic modification in a process
whereby the expression of genes involved in BAT function are induced in WAT, thus resulting in
brite (“bright” or “beige”) adipocytes [36,43]. This WAT browning is achieved by key transcription
factors, including PR domain-containing protein 16 (PRDM16) and peroxisome proliferator-activated
receptors (PPARs) [5,44]. Indeed, PPARA (PPAR-alpha) activation promotes beige adipogenesis via
PRDM16 and PGC1A [5,6]. Moreover, PPARG (PPAR-gamma) is indispensable for both WAT and BAT
formation [45,46], and PPARG activators/agonists may be used to induce browning of WAT [11,47].
Typical BAT develops much earlier in life than WAT but both share similar transcription cascades which
involve PPARG and CCAAT/enhancer-binding proteins (C/EBPs) [48]. Of note, fully functional brite
adipocytes have been found in both infants and adults on cold exposure [49]. As will be detailed in the
following sections, certain microRNAs regulate BAT and WAT function and differentiation [50–52].
Such microRNAs regulating white, brown, and brite adipogenesis often target key transcription
factors (e.g., PRDM16; PPARG; C/EBPB; PGC1A/B; and Early B-cell factor transcription factor 2, EBF2),
thus, elucidating their specific adipogenic role and functions is emerging as an important aspect of
AT biology.
1.4. Transcription Factors and Browning Agents
PPARs represent a group of nuclear proteins which function as transcription factors [53].
Two members of this family, i.e., PPARA and PPARG, play a pivotal role in AT development and
differentiation [11]. As aforementioned, PPARG is highly expressed in both WAT and BAT [11] and
constitutes the master transcription factor in the differentiation program of BAT. As such, PPARG has
a crucial role for tissue development, function and survival, inducing UCP1 expression during
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adipogenesis [11]. Conversely, PPARA induces PGC1A, with PPARA ablation decreasing BAT specific
genes (e.g., Zic family member 1, LIM homeobox 8, and PRDM16) [54].
PRDM16 is a zinc-finger protein which controls the switch between skeletal myoblasts and brown
adipocytes [44], and stimulates adipogenesis by directly binding to PPARG [44]. PRDM16 also binds to
and co-regulates many other regulators (e.g., PGC1A; PGC1B; C/EBPs; EBF2; and Euchromatic Histone
Lysine Methyltransferase 1, EHMT1) to promote brown adipocyte specific gene induction [54]. Thus,
PRDM16 configures a transcriptional complex with C/EBPB which controls the cell fate switch from
MYF5+ cells to brown pre-adipocytes and activates PPARG expression, inducing the thermogenic
program [55]. PRDM16 is essential for embryonic BAT development. However, recent studies have
shown that BAT is not affected in Prdm16 knockdown mice, suggesting that other factors also mediate
these functions [55]. Notably, PRDM16 appears to be required for the maintenance of BAT function
during aging in mice [56].
C/EBPs are transcription factors which control the differentiation of a range of cell types and gene
expression in early adipogenesis [57]. C/EBPB and C/EBPD regulate the expression of C/EBPA and
PPARG involved in the last stage of adipogenic differentiation [57]. In addition, C/EBPA functions to
maintain PPARG expression and cooperatively regulates gene transcription to promote and maintain
the differentiation of adipocytes, insulin sensitivity, and glucose and lipid metabolism [58].
PGC1A is a cold inducible co-activator of PPARA and PPARG and a key regulator of mitochondrial
biogenesis, adaptive thermogenesis, and oxidative metabolism [59]. Conversely, the transcription
repressor receptor–interacting protein 140 (RIP140) inhibits adipogenesis and is able to block the effects
of PGC1A [60]. Notably, mice devoid of RIP140 are lean and have increased oxygen consumption,
whilst being resistant to obesity induced by high-fat diet (HFD) [60]. Moreover, EBF2 is an essential
mediator of brown adipocyte commitment and terminal differentiation, playing a crucial role in
adequate PPARG binding to UCP1 [61].
1.5. MicroRNA Function and Regulatory Mechanisms
MicroRNAs (miRNAs) constitute a class of short (20–24 nucleotide) non-coding, single stranded
RNAs that regulate gene expression at the post transcriptional level by binding to the mRNA of the
target gene [62]. Following their discovery in the 1990s [63], miRNAs have been shown to regulate
a wide spectrum of biological processes and are implicated in metabolism and the pathophysiology
of multiple diseases whilst may also serve as corresponding diagnostic biomarkers [64–67]. Indeed,
miRNAs are now regarded to play a key role in AT biology, implicated in regulating the differentiation
and function of both WAT and BAT [50–52].
MiRNAs function by binding to the RNA-induced silencing complex (RISC), and through this
by subsequently binding to the 3’ untranslated regions (3’ UTR) of mRNAs causing translational
repression or mRNA degradation [68,69]. Initially, miRNAs are transcribed by RNA-polymerase II
as 5′-capped polyadenylated precursors which are known as primary miRNA (pri-miRNA) [70,71].
After transcription, this pri-miRNA undergoes maturation by Drosha which releases a small hairpin
shaped RNA in the nucleus, called pre-miRNA [70]. In turn, pre-miRNA is exported to the cytoplasm
by exportin-5 and is cleaved by DICER to form a small RNA duplex (Figure 1) [72]. Two mature miRNA
species may be generated from the 3′ end (passenger strand) and the 5′ end (leading strand) of a
pre-miRNA precursor. Only one species remains viable in most cases, whilst the complementary species
is degraded; however, co-existence of miRNA-5p and -3p species is increasingly being reported [73].
MiRNAs are also found in blood, urine, and extracellular fluid, packaged inside lipid or lipid
protein complexes, such as microvesicles, exosomes, or apoptotic bodies [74,75]. Specific miRNAs tend
to be preferentially released by cells and, thus, are more prone to be found in the circulation [76]. Of note,
AT-specific disruption of miRNA processing by knockdown of DICER and DiGeorge syndrome critical
region 8 (DGCR8) has been shown to alter WAT accumulation and promote whitening of BAT, leading
to impaired metabolic function [77–79]. Moreover, Mori et al. reported whitening of inter-scapular
BAT in mice with a fat-specific DICER knockdown [78], while MiR-365, MiR-346 and MiR-362 rescued
Cells 2020, 9, 2489 5 of 34
the whitening phenotype in DICER knockout mice [79]. Such studies provide evidence that supports
an important role that miRNAs play in the functioning of both WAT and BAT, as detailed in the
following sections. Intriguingly, the study by Thomou et al. showed that AT is a major source of
circulating exosomal miRNAs and that mice with an AT-specific DICER knockout (ADicerKO) have
reduced levels of circulating exosomal miRNA [75]. This study further showed that transplantation
of WAT and BAT into ADicerKO mice restores the circulating levels of various miRNAs which are
related with glucose tolerance improvement and decreased hepatic Fgf21 mRNA and circulating FGF21
levels [75]. This further suggests that AT-derived circulating miRNAs can impact on the regulation of
gene expression in distant tissues, thus acting as another form of adipokines [75].Cells 2020, 9, x 5 of 35 
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Figure 1. Brief schematic representation of the microRNA (miRNA) processing pathway. The primary
transcripts of miRNAs, called pri-miRNAs, are transcribed by RNA polymerase II. The RNase III
enzyme Drosha further processes the pri-miRNAs into hairpin shape precursors of 70 to 100 nucleotides
(nt) called pre-miRNA, which are then exported to the cytoplasm by exportin-5 for further processing.
In the cytoplasm, another RNase III enzyme, Dicer, cleaves the pre-miRNAs to form linear double
stranded intermediate miRNA called miRNA duplex. The ∼22-nucleotide long mature miRNAs strand
obtained from the intermediate duplex is then loaded into the RNA-induced silencing complex (RISC)
to silence the target messenger RNA (mRNA) by destabilizing it and/or inhibiting its translation.
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2. MicroRNAs in BAT
Certain miRNAs have been reported to specifically regulate BAT, including MiR-193b-365,
MiR-182-203, MiR-106a-93, MiR-328, and MiR-129 [71,80]. These miRNAs target important thermogenic
genes with either positive or negative impact on the BAT thermogenic program [71,80]. Moreover,
various miRNAs, such as the MiR-193b-365 cluster, MiR-328, MiR-378, MiR-30b/c, MiR-455, and MiR-32,
are activators of brown adipogenesis, whereas MiR-34a, MiR-133, MiR-155, and MiR-27b are brown
adipogenesis inhibitors (Table 1 and Figure 2) [81–84]. Manipulation of these miRNAs has been shown
to affect uncoupled respiration, glucose uptake, and thermogenesis, as well as whole-body energy
expenditure, glucose tolerance, and insulin sensitivity [6,71,80]. Consequently, these miRNAs represent
potentially important therapeutic targets for the treatment of obesity and related metabolic disorders,
such as T2DM.
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Figure 2. Key microRNAs (miRNAs) regulating brown adipose tissue (BAT), brite (beige or
brown-in-white) adipose tissue, and white adipose tissue (WAT).
MiR-193b-365: MiR-193b and MiR-365 form a cluster that is located on chromosome 16 [85].
This cluster is highly expressed in BAT and is involved in the regulation of BAT differentiation, directly
targeting Runx1t1 (Runt-related transcription factor 1; translocated to, 1; which is an adipogenesis
inhibitor) [85]. Moreover, the MiR-193b-365 cluster is positively regulated by PRMD16 [81]. Interestingly,
Sun and colleagues reported that MiR-365 was sufficient to promote Ucp1 expression in Dicer knockout
mice [85]. However, in vivo studies showed that blocking this miRNA cluster does not change
BAT morphology and the expression of BAT-related markers (UCP1 and PRMD16) [107]. Moreover,
Oliverio et al. showed that MiR-193b regulates BAT differentiation by targeting a β-secretase
(i.e., beta-site amyloid precursor protein cleaving enzyme 1; BACE1) which promotes myogenic
differentiation [86]. This study also showed that loss of MiR-193 in brown adipocytes attenuated key
thermogenic genes (Cidea, Ucp1, Pgc1a and Prdm16) [86]. It is therefore evident that this miRNA cluster
is implicated in BAT regulation, but further studies are clearly required to clarify its exact function(s).
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Table 1. Selected key microRNAs (miRNAs) and their reported effects in brown adipose tissue (BAT).
miRNA Function(s) Target(s) * Reference(s) andCorresponding Study Model(s)
MiR-193b-365 Involved in the regulation ofBAT differentiation Runx1t1
[85]: Mouse; in vitro
[86]: Mouse; in vitro
MiR-182 Positive regulator of BAT adipogenesis Insig1, Pdgfr2 [77]: Mouse; in vitro
MiR-203 Positive regulator of BAT adipogenesis Insig1, Pdgfr2 [77]: Mouse; in vitro
MiR-106b-93 Negative regulator of BAT differentiation,involved in energy homeostasis Ppara [87]: Mouse
MiR-328
Positive regulator of BAT differentiation,
controls brown adipogenesis by
regulating the switch between
muscle-specific (myogenic) and brown
adipogenic lineages
Bace1 [86]: Mouse; in vitro[88]: Mouse; in vitro
MiR-129
Positive regulator of BAT function,
involved in thermogenesis and energy
expenditure, potential obesity biomarker
Igf2, Egr1 [89]: Human; mouse; in vitro
MiR-455 Positive regulator of brown/beige AT,promotes cells differentiation
UCP1, Runx1t1,
Necdin, Hif1an, Tgfbr3
[90]: Human; mouse; in vitro
[91]: In vitro
[92]: Mouse
MiR-30b/c Positive regulator of brown andbrite adipogenesis Rip140
[93]: Mouse; in vitro
[94]: In vitro
MiR-34a
Negative regulator of brown and brite
adipogenesis, exhibiting increased
expression in obesity
Fgfr1 [95]: Mouse; in vitro
MiR-27b
Inhibitor of brown and beige
adipogenesis, exhibiting decreased
expression in response to cold exposure
and β-adrenergic activation
Prdm16, Ppar, Pparg,
Creb, Pgc1b, Prohibitin
[96]: In vitro
[97]: Mouse; in vitro
[98]: In vitro
MiR-378
Positive regulator of BAT that promotes
Ucp1 expression, BAT mass and BAT
oxygen consumption, showing increased
expression during brown
adipocyte differentiation
Pde1b [99]: Mouse; in vitro
MiR-133
Negative regulator of brown
adipogenesis, acting as an inhibitor of
BAT differentiation
Prdm16
[100]: Mouse; in vitro
[101]: Mouse; in vitro
[102]: In vitro
MiR-155
Negative regulator of brown
adipogenesis, enriched in BAT and highly
expressed in proliferating brown
pre-adipocytes, exhibiting declining
expression with cell differentiation
C/ebpb
[103]: Mouse; in vitro
[104]: Mouse; in vitro
[105]: Human; mouse; in vitro
MiR-32
Positive regulator of brown adipogenesis
with significantly increased expression in
BAT during cold exposure
Tob1 [106]: Mouse; in vitro
* All abbreviations are detailed in the list of abbreviations of the manuscript.
MiR-182 and MiR-203: MiR-182 and MiR-203 are positive regulators of BAT adipogenesis, targeting
Insig1 (Insulin-induced gene 1) and Pdgfr2 (Platelet-derived growth factor receptor 2) [77,81]. These BAT
specific miRNAs are essential for the maintenance and differentiation of brown adipocytes in vivo [77].
Inhibition of MiR-182 or MiR-203 causes reduction in BAT adipogenic markers (e.g., UCP1, PGC1A,
CIDEA) and mitochondrial markers (e.g., cytochrome c oxidase subunit 7), as well as downregulation
of genes which control the respiratory electron transport and oxidative phosphorylation, whilst the
complementary species is degraded [77]. When comparing the miRNA profiles in mouse and human
BAT, Güller and colleagues found that MiR-182 and MiR-203 were part of the top ten miRNAs targeting
the most genes involved in growth and development in mouse BAT; however, only MiR-203 was
conserved in human BAT [108]. The absence of MiR-182 expression in human BAT might contribute to
differences between mouse and human BAT development and function.
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MiR-106b-93: MiR-106b and MiR-93 form a cluster that targets PPARA and acts as a negative
regulator of BAT differentiation [109]. This cluster is a member of the MiR-17 family which controls
stem cell differentiation in the developing mouse embryo [81]. MiR-106b-93 expression increases during
brown adipocyte differentiation and in BAT under a HFD, but not in WAT [110]. Of note, MiR-106b-93
inhibition has been shown to induce brown adipogenic markers (e.g., UCP1, PRMD16, CIDEA,
PPARA, PGC1A), as well as fatty acid-binding protein 4 (FABP4, also known as adipocyte protein 2,
AP2), PPARG and adiponectin, and promote lipid droplet accumulation in brown adipocytes [109].
Interestingly, in mice, the expression of this cluster is increased in BAT by obesity [87], whilst
overexpression of this cluster has been shown to suppress Ucp1 expression [84]. Overall, this miRNA
cluster is thought to play a significant role in energy homeostasis through negative regulation of
brown adipocytes.
MiR-328: MiR-328 is a positive regulator of BAT differentiation which targets Bace1, with MiR-328
inhibition in brown adipocytes resulting in downregulation of thermogenic gene expression (Cidea,
Ucp1, Pgc1a and Prmd16) [86,88]. Additionally, overexpression of this miRNA has been shown to
instigate BAT differentiation and increase C/EBPB and UCP1 levels, as well as oxygen consumption
rates in BAT, and can also impair muscle progenitor commitment [86]. Moreover, sequence similarities
have been identified between MiR-193b and MiR-328, which appear to be co-expressed in most tissues,
with enrichment in BAT and WAT and significant overlap between their target gene sets [86]. Overall,
MiR-328 is considered to control brown adipogenesis by regulating the switch between muscle-specific
(myogenic) and brown adipogenic lineages [86,111].
MiR-129: MiR-129 is a positive regulator of BAT function which is involved in thermogenesis
and energy expenditure [92,112]. This miRNA targets both Igf2 (insulin like growth factor 2) and Egr1
(Early growth factor response 1), with both these factors being UCP1 inhibitors [92,112]. A recent study
by Fu et al. showed that MiR-129 also directly targets ATG7 (Autophagy-related gene 7), which is an
essential autophagy gene [89]. Indeed, this study showed that MiR-129-5p inhibits adipogenesis by
autophagy, demonstrating increased expression of MiR-129-5p in the AT of db/db mice. Furthermore,
MiR-129-5p inhibition was shown to significantly inhibit adipocyte differentiation and white adipocyte
browning in vitro, decreasing the level of specific markers (e.g., FABP4, UCP1, and PPARG) in mature
white and brown adipocytes [89]. Elevated serum MiR-129-5p levels were also documented in patients
with obesity, suggesting that this miRNA maybe a potential obesity-related biomarker [89].
3. MicroRNAs Regulating BAT and Brite
Compelling evidence indicates that an increasing number of miRNAs appear to regulate both BAT
and brite AT (Figure 2), including MiRNA-455, MiRNA-30b/c, MiRNA-34a, MiRNA-27, MiRNA-378,
MiRNA-133, MiRNA-155, and MiRNA-32.
MiR-455: MiR-455 is a key positive regulator of brown/beige AT [90,91], exhibiting BAT specific
expression which can be induced upon cold exposure or bone morphogenetic protein-7 (BMP-7)
stimulation [90]. Zhang and colleagues have elegantly demonstrated that MiR-455 targets Runx1t1,
Necdin, and hypoxia inducible factor 1 subunit alpha inhibitor (Hif1an), reducing the hydroxylation of
Asn173 on AMP-activated protein kinase alpha1 (AMPKa1) by Hif1an, and thus enhancing AMPKa1
activity [90]. This leads to increased Pgc1a expression, mitochondrial biogenesis, as well as the
expression of genes involved in fatty acid mobilization and lipolysis [90]. Furthermore, this study
also demonstrated that MiR-455 overexpression in committed brown and white pre-adipocytes and
non-committed multipotent progenitors promotes cell differentiation, increasing lipid accumulation and
expression of adipogenic and brown adipocyte genes (Ucp1, Pparg and Pgc1a) [90]. Adipose-specific
MiR-455 transgenic mice were reported to show marked browning in inguinal WAT and scWAT,
higher maximal thermogenic capacity, improved cold resistance, insulin sensitivity, glucose tolerance,
and reduced weight gain upon HFD, as well as better lipidemic profiles [90]. Moreover, MiRNA-455
knockdown mice have been shown to have decreased BAT and WAT mass and suppressed expression
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of Ucp1, Pgc1a, Pparg in BAT, and C/ebpa in scWAT [90]. MiR-455 inhibition was also shown to suppress
brown adipogenesis and reduce the expression of Ucp1 and Pgc1a in brown adipocytes [90].
Another study by Cai et al. demonstrated that Ucp1 is a target for MiR-455 during adipogenic
differentiation in 3T3-L1 pre-adipocytes [91]. Indeed, this study showed that MiR-455 downregulates
Ucp1 expression through interaction with a target site of MiR-455 in the coding region of mouse
Ucp1 [91]. Another study by Pahlwani et al. showed MiR-455 thermogenic effects by targeting key
brown adipogenic signaling molecules including Hif1an, Pparg, and type III transforming growth
factor-β receptor (Tgfbr3) [92]. Notably, Hif1an appears to serve as an intermediate target between
MiR-455 and Notch1, with MiR-455 reducing Notch1 expression which, in turn, promotes WAT
browning [92]. In addition, in this study, MiR-455 also downregulated Tgfbr3 and Smad2/3 (a member of
its downstream pathway), leading to enhanced energy expenditure and improved metabolic profile [92].
MiR-30b/c: The miRNAs of the MiR-30 family are highly expressed in BAT and WAT, and are
known to promote adipogenesis and inhibit osteogenesis [93,94]. MiR-30a regulates WAT as will be
discussed in the following section [113], whilst MiR30b/c are the main positive regulators of brown
and brite adipogenesis [93]. MiR-30b/c levels are markedly increased during adipocyte differentiation
and are stimulated by cold exposure or β-adrenergic receptor activation [93]. MiR30b/c directly targets
Rip140, a corepressor of the thermogenic genes, and promotes thermogenesis and development of
brite AT [93,94]. As such, MiR30b/c overexpression induces mitochondrial and thermogenic genes
(Ucp1, Cidea) and mitochondrial respiration in brown and brite AT [93]. Moreover, MiR30b/c also
enhances the expression of thermogenic genes in SVF derived from inguinal WAT [93], whist MiR30b/c
overexpression also induces thermogenic genes in subcutaneous WAT (scWAT) [93,94].
MiR-34a: MiR-34a is a negative regulator of brown and brite adipogenesis, exhibiting increased
expression in obesity [114]. This miRNA directly targets fibroblast growth factor receptor 1 (Fgfr1)
and disrupts FGF21 signaling in AT, thus preventing PGC1A activation and browning of WAT [114].
As such, MiR-34a downregulation promotes FGF21 signaling which induces increased nicotinamide
adenine dinucleotide (NAD+) levels, Sirt1 expression and PGC1A deacetylation and browning that
improves the overall metabolic profile [114]. Accordingly, MiR-34 blockage leads to reduced adiposity,
improved circulating levels of insulin, FGF21, glucose, triglycerides and FFA, as well as increased
mitochondrial DNA copy number and oxidative function in WAT [71,110]. The latter was also shown
by MiR-34a downregulation in differentiated 3T3-L1 adipocytes [114].
Moreover, MiR-34a downregulation has been shown to act against HFD-induced obesity in
mice, reducing adiposity and leading to normalization of food intake, decreased body weight and
WAT mass [114]. MiR-34a inhibition also promotes brown and beige adipogenesis by regulating
brown adipogenic markers (UCP1, PRMD16, PGC1α) and enhancing mitochondrial function in BAT
and WAT [114]. Interestingly, Ge et al. have reported that myostatin post-transcriptionally inhibits
fibronectin type III domain containing 5 (Fndc5) expression via MiR-34a in both myoblasts and
adipocytes [95]. Indeed, myostatin appears to regulate Fndc5/Irisin expression and secretion (irisin
represents a cleaved and secreted fragment of the FNDC5 membrane protein) via a MiR-34a-dependent
mechanism, with loss of myostatin in mice leading to increased Fndc5/Irisin expression which
contributes to WAT browning [95]. In this context, it also noteworthy that irisin has been reported to
induce WAT browning via activation of Ucp1 expression [115]. These latter effects remain to be further
confirmed by additional research studies.
MiR-27b: MiR-27b is an inhibitor of brown and beige adipogenesis, exhibiting decreased expression
in response to cold exposure and β-adrenergic activation [97]. MiR-27b targets Prmd16, Ppara,
Pparg, cAMP-response element binding protein (Creb), Pgc1b and prohibitin, and is downregulated
during WAT and brite differentiation [96–98]. MiR-27b is the upstream inhibitor of Pparg in WAT
differentiation, and its inhibition leads to enhanced expression of brown adipogenic marker genes
(Ucp1, Prmd16, Ppara/g, Cidea, Pgc1a) in pre-adipocytes from inguinal WAT and visceral AT, as well as
an increased number of brite cells in inguinal WAT [116]. Furthermore, Yu et al. have shown that high
expression of MiR-27b-3p in epididymal WAT inhibits browning and leads to visceral AT accumulation,
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with MiR-27b-3p inhibition enhancing browning in epididymal WAT of HFD-fed mice and leading to
weight loss and improved insulin sensitivity [116].
MiR-378: MiR-378 is expressed within the PGC1B gene and is considered a positive regulator
of BAT and a negative regulator of brite adipogenesis [117]. Indeed, Pan et al. have shown
that phosphodiesterase 1b—PDE1B is a phosphodiesterase that catalyzes the cGMP and cAMP
turnover [118]—is targeted by MiR-378 in BAT, but not in WAT [117,118]. This leads to diminished
degradation of cAMP to AMP, with elevated cAMP levels activating the PKA and downstream signaling
pathways [117]. Overall, MiR-378 has been shown to promote BAT mass, BAT oxygen consumption and
Ucp1 expression, showing increased expression during brown adipocyte differentiation [117]. As such,
MiR-378 has been shown to protect against both genetic and HFD-induced obesity in mice [117].
Moreover, MiR-378 transgenic mice exhibit increased BAT mass and cell number, reduced WAT mass
and increased energy expenditure [117]. Interestingly, this study also noted that the expansion of BAT,
rather than the MiR-378 per se, resulted in suppressed formation of beige adipocytes in scWAT [117].
Finally, decreased Ucp1 and Prmd16 expression in inguinal WAT was shown with overexpression of
MiR-378, without changes in the levels of the adipogenic markers PPARG and AP2 [117]. Notably,
Kim et al. have shown that eicosapentaenoic acid (an omega 3 fatty acid) binds to and activates the free
fatty acid receptor 4 (FFAR4; a functional receptor for polyunsaturated fatty acids), which positively
modulates MiR-378, resulting in increased Ucp1 expression and cAMP levels [99].
In addition, Zhang et al. reported that MiR-378 prevents and treats obesity in mice by activating
the pyruvate-phosphoenolpyruvate futile cycle in the muscle and enhancing lipolysis in adipose
tissues [119]. This study also highlighted that transgenic mice overexpressing MiR-378 provide a
genetic system for investigating the metabolic crosstalk between different tissues at the whole-body
level [119]. Overall, MiR-378 appears to mediate a wide range of biological processes implicated in
cancer, angiogenesis, hepatosteatosis, and T2DM [120].
MiR-133: MiR-133 has two isomers (MiR-133a and -133b) with highly similar sequences, differing
only at the 3′-terminal base, with MiR-133a-1/2 and MiR-133b terminating with G-3′ and A-3′,
respectively [121]. MiR-133 is a negative regulator of brown adipogenesis, acting as an inhibitor
of BAT differentiation which targets Prmd16 [100–102]. MiR-133 is highly expressed in BAT and
inguinal WAT, whilst it is also enriched in muscle tissue and myogenic cells [100]. Downregulated
MiR-133 levels in BAT and scAT are noted after cold exposure as a result of decreased expression of its
transcription regulator myocyte enhancer factor-2 (Mef2), resulting in increased Prmd16 expression
and upregulation of thermogenic genes [100]. Double knockout of MiR-133a (there are two alleles
for MiR-133a with identical sequences, namely, MiR-133a1 and MiR-133a2, which are located on
different chromosomes) in mice increased the program of thermogenic genes in scAT and inguinal
WAT, resulting in browning/beigeing of these cells [100].
Furthermore, Yin et al. showed that MiR-133 overexpression in primary brown pre-adipocytes
strongly impaired their adipogenic differentiation, and decreased the levels of browning genes
(Ucp1, Cidea, Pgc1a, Prmd16) and general adipogenic genes (Adipoq, C/ebpb, Fabp4 and Pparg) [101].
Taken together, these studies indicate that MiR-133 (MiR-133a and -133b) plays a critical role in
suppressing brown adipogenesis via inhibition of Prmd16.
MiR-155: MiR-155 is another negative regulator of brown adipogenesis which targets C/ebpb [103–105].
MiR-155 is enriched in BAT, being highly expressed in proliferating brown pre-adipocytes and exhibiting
declining expression with cell differentiation [103–105]. Of note, C/EBPB is crucial for brown and
beige adipocyte differentiation, with C/ebpb knockdown resulting in BAT defects [122]. MiR-155 is
negatively regulated by C/EBPB, thus forming a double feedback loop [103]. Moreover, MiR-155 is
positively regulated by transforming growth factor beta (TGFB), exhibiting induction upon TGFB
treatment [103,105]. MiR-155 deficient mice show a high cellular respiration rate and increased number
of brown-like adipocytes in inguinal WAT after cold exposure [103]. Similarly, HFD-fed MiR-155
knockout mice were shown to gain 56% less weight in comparison to wild type [104]. MiR-155
deficient adipocytes showed upregulated brown (Ucp1, Cidea, Pparg) and white (Fabp4; Adipoq; fatty
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acid synthase; and Patatin-like phospholipase domain-containing protein 2, Pnpla2) adipogenic genes
and glucose metabolism genes (Insulin receptor substrate 1, Irs1; and Glucose Transporter Type 4,
Glut4) [104]. Overall, MiR-155 deletion can increase thermogenesis and insulin sensitivity, whilst
limiting inflammation in WAT and preventing diet-induced obesity in mice [104]. Indeed, transgenic
mice overexpressing MiR-155 show reduced BAT mass, altered BAT morphology and lower levels of
thermogenic markers without alteration in body weight and food intake [103].
Similarly, Karkeni et al. showed that overexpression of MiR-155 is associated with increased
inflammatory state in adipocytes [105]. This study showed up-regulation of MiR-155 in biopsies of
subjects with obesity where the induction of MiR-155 was correlated with tumor necrosis factor alpha
(TNFA) expression and BMI [105].
MiR-32: MiR-32 is a positive regulator of brown adipogenesis with significantly increased
expression in BAT during cold exposure, promoting BAT thermogenesis and inguinal WAT
browning [106]. As such, MiR-32 has been shown to be a BAT specific super enhancer which targets
Tob1 (Transducer of erbB2 1; a p38/AMPK signaling repressor) [106]. Targeting Tob1 or diminishing its
repressive effect on p38/MAPK results in ATF2 (Activating Transcription Factor 2) phosphorylation and
activation of enhanced BAT thermogenesis and transactivation of WAT browning [106]. Interestingly,
BAT-specific MiR-32 overexpression has been shown to result in increased BAT thermogenesis, as well
as increased FGF21 serum levels which further promote WAT browning [106]. Therefore, MiR-32 and
Tob1 appear to be modulators of FGF21 signaling, which can be manipulated for therapeutic effects
against obesity and the metabolic syndrome [106].
4. Micro RNAs Regulating Brite AT
MiR-196a, MiR-26, MiR-125, and Let-7 are key miRNAs, which have been reported to mainly
regulate brite AT (Table 2 and Figure 2).
MiR-196a: MiR-196a targets certain homeobox (HOX) genes in human pre-adipocytes [127],
playing a role in the browning of white progenitor cells and inducing WAT browning with enhanced
expression of brown adipogenic genes (C/ebpb, Prmd16, Ucp1 and Pgc1a) [78]. Indeed, MiR-196a
is a positive regulator of brite adipogenesis and promotes browning by directly binding to and
suppressing Homeobox C8 (Hoxc8, a determinant of white adipogenesis) [78]. MiR-196a expression
is induced by cold exposure and β-adrenergic stimulation, whilst HOXC8 directly suppresses the
expression of C/ebpb in cooperation with histone deacetylase 3 (HDAC3) in scAT [78]. Notably,
mice overexpressing MiR-196a showed resistance to obesity and improved glucose metabolism [78].
Furthermore, Divoux et al. demonstrated higher MiR-196a expression in the gluteal AT depot leading
to decreased fat development in this depot, whilst higher MiR-196a expression in the abdominal depot
seems beneficial and associated with decreased fat mass [127]. Finally, using functional studies and
transcriptomic profiling of MiR-196a knockdown pre-adipocytes, Hilton et al. showed that MiR-196a
regulates pre-adipocyte proliferation and extracellular matrix pathways, highlighting that this miRNA
is involved in the regulation of human body fat distribution [128]. This study also documented that a
single nucleotide polymorphism (rs11614913) in pre-MiR-196a-2 influences the expression of MiR-196a
in abdominal scAT and is associated with the waist-to-hip ratio [128].
MiR-26: MiR-26a and MiR-26b are identified as key regulators of human white and beige
adipocyte differentiation, constituting positive regulators of brown adipogenesis that targets ADAM
metallopeptidase domain 17 (ADAM17) [123], which is an anti-adipogenic and anti-browning
factor [129]. The MiR-26 family consists of three members (MiR-26a1, MiR-26a2 and MiR-26b),
which are upregulated in early adipogenesis, and their inhibition prevents lipid accumulation, whilst
their overexpression accelerates it [124]. MiR-26 levels increase during WAT differentiation, and MiR-26a
is enriched in BAT and induced in WAT upon cold response [123]. MiR-26a promotes UCP1 and
PGC1A expression and can induce oxygen consumption in human brite adipocytes [123]. Moreover,
mimics of MiR-26a/b have been shown to promote white and beige adipogenesis causing induction
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of brown adipogenic markers (UCP1, PGC1A, AP2, and PRDM16) and brown-like mitochondrial
morphology [123].
Of note, a recent study by Acharya and colleagues reported that MiR-26 plays a critical role in
regulating adipogenesis in vitro and in vivo by suppressing adipocyte progenitor cell differentiation
and fat production by targeting Fbxl19 (gene encoding the F-box and leucine rich repeat protein
19; FBXL19), which encodes a component of Skp–Cullin–F-box-containing (SCF) E3 ubiquitin ligase
complexes [124]. Indeed, FBXL19 mediates targeted ubiquitylation of proteins destined for proteasomal
degradation [130], and appears to be a novel MiR-26 target that functions downstream from this
miRNA to drive adipogenesis [124]. Interestingly, loss of MiR-26 results in dramatic AT expansion early
in adult life and triggers precocious adipocyte progenitor cell differentiation, resulting in adipocyte
hyperplasia and WAT expansion in a manner that resembles the physiologic response to caloric
excess [124]. Over time, excessive adipocyte progenitor cell differentiation leads to depletion of
this progenitor compartment, as seen in older MiR-26-triple-knockout mice (knockout of MiR-26a-1,
MiR-26a-2, and MiR-26b) which exhibit impaired weight gain and adipogenesis when fed a HFD [124].
However, MiR-26 overexpression in the adipocyte progenitor cells lineage was sufficient to block
HFD-induced weight gain, adipose tissue expansion, hyperglycaemia, and hyperlipidaemia [124].
MiR-125: The MiR-125 family consist of two subfamilies: MiR-125a and MiR-125b, each further
divided into 3p and 5p, which respectively derive from the 3′- or 5′-end of pre-MiR-125a and
pre-MiR-125b [131]. MiR-125b-5p is identified as negative regulator of browning and the formation of
functional brite adipocytes [132]. MiR-125b-5p is highly expressed in WAT and low in BAT; however,
its expression decreases during browning and shows a proportional inverse association to UCP1
expression [132]. Notably, injection of MiR-125b-5p into inguinal WAT can inhibit brite adipocyte
formation and mitochondrial biogenesis [132]. MiR-125b-5p overexpression in scAT of mice attenuates
the Ucp1, Cidea, and Prmd16 expression and reduces large lipid droplets [132]. Furthermore, inhibition
of this miRNA increases UCP1 and CIDEA levels and results in smaller lipid droplets [132]. Similarly,
overexpression of MiR-125b-5p in human multipotent adipose-derived stem (hMADS) cells inhibited
oxygen consumption and mitochondrial DNA content [132]. Using microarray-analysis, Rockstroh
and colleagues showed that MiR-125b-5p is upregulated during human adipocyte differentiation and
identified the matrix metalloproteinase 11 (MMP11) as a direct target of MiR-125b-5p [125]. MMP11
overexpression decreased AT accumulation, indicating that MMP11 acts as an anti-adipogenic regulator,
whereas overexpression of MiR-125b-5p itself reduced adipogenesis [125].
Let-7: The Let-7 family of miRNAs is composed of 13 miRNA precursors giving rise to 10
distinct mature Let-7 miRNAs, with highly conserved sequence and function across species [70].
Dysregulated expression of the Let-7 family is associated with various diseases, such as cancer, lung,
and CVD [126]. Furthermore, the Let-7 family is reported to target high-mobility group AT-hook
2 (HMGA2) and is considered involved in adipogenesis, glucose metabolism, insulin resistance,
and inflammation [133,134]. A recent study by Youssef et al. showed that Let-7 is an important
regulator of adipogenesis in 3T3-L1 cells, with Let-7a-5p being downregulated in HFD-fed rats [135].
Let-7 is upregulated after induction of adipogenesis by either the standard adipogenic cocktail
containing dexamethasone, isobutylmethylxanthine, and insulin or the combination of rosiglitazone
and insulin [133]. Furthermore, Let-7 is much more abundant in mature adipocytes than pre-adipocytes
derived from mouse epididymal AT [133]. Let-7 overexpression has been shown to block 3T3-L1 cell
growth and completely inhibit terminal differentiation as measured by lipid accumulation and marker
genes [133].
Finally, Let-7i-5p is also a thermogenesis inhibitor, strongly inhibiting mitochondrial and browning
marker genes (e.g., Ucp1, Prmd16, Cidea, and citrate synthase) in mice scAT and human and murine
brite adipocytes [126]. Injection of Let-7i-5p into murine scAT impaired the formation and function of
brite adipocytes, whilst significant reduction in Let-7i-5p expression was noted upon β3-adrenergic
stimulation [126]. Let-7i-5p overexpression led to inhibition of basal oxygen consumption and decreased
UCP1 expression in hMADS brite adipocytes [126]. However, using miRNA-target prediction tools,
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this study showed that UCP1 was not a putative target of Let-7i-5p [126]. Overall, Let-7i-5p levels are
associated with brite adipocyte formation and function in both mice and humans and may represent
a potential new regulator of energy expenditure [126]. Additional targets for Let-7 have also been
identified, including E2f6 (E2F transcription factor 6), Cdc34 (cell division cycle 34), and Igf2bp1
(insulin-like growth factor 2 mRNA-binding protein 1) genes [136–139].
Table 2. Selected key microRNAs (miRNAs) and their reported effects in brite (beige or brown-in-white)
adipose tissue.
miRNA Function(s) Target(s) * Reference(s) andCorresponding Study Model(s)
MiR-196a
Plays a role in browning of white
progenitor cells, inducing WAT
browning and involved in regulating
human body fat distribution
Hoxc8 [78]: Mouse; in vitro
MiR-26
Key regulator of human white and beige
adipocyte differentiation and positive
regulator of brown adipogenesis
ADAM17, Fbxl19 [123]: Human; in vitro[124]: Mouse; in vitro
MiR-125 Negative regulator of browning and theformation of functional brite adipocytes MMP11 [125]: Human; in vitro
MiR-Let7i-5p
Thermogenesis inhibitor, strongly
inhibiting mitochondrial and browning
markers in mice scWAT and human and
murine brite adipocytes
Not specified [126]: Human; mouse; in vitro
MiR-455 Positive regulator of brown/beige AT Ucp1, Runx1t1, Necdin,Hif1an, Tgfbr3
[90]: Human; mouse; in vitro
[91]: In vitro
[92]: Mouse
MiR-30b/c Positive regulator of brown andbrite adipogenesis Rip140
[93]: Mouse; in vitro
[94]: In vitro
MiR-34a
Negative regulator of brown and brite
adipogenesis, exhibiting increased
expression in obesity, disrupts FGF21
signaling in AT and prevents PGC1A
activation and browning of WAT
Fgfr1 [95]: Mouse; in vitro
MiR-27b
Inhibitor of brown and beige
adipogenesis, downregulated during
WAT and brite differentiation
Prmd16, Ppara, Pparg,
Creb, Pgc1b, Prohibitin
[96]: In vitro
[97]: Mouse; in vitro
[98]: In vitro
MiR-378 Negative regulator of brite adipogenesis Pde1b [99]: Mouse; in vitro
MiR-133 Negative regulator ofbrown adipogenesis Prmd16
[100]: Mouse; in vitro
[101]: Mouse; in vitro
[102]: In vitro
MiR-155 Negative regulator ofbrown adipogenesis C/ebpb
[103]: Mouse; in vitro
[104]: Mouse; in vitro
[105]: Human, Mouse; in vitro
MiR-32
Positive regulator of brown
adipogenesis, promoting thermogenesis
and WAT browning
Tob1 [106]: Mouse; in vitro
* All abbreviations are detailed in the list of abbreviations of the manuscript.
5. MicroRNA in WAT
An array of miRNAs have been identified in WAT, which are largely involved in the regulation
of adipocyte differentiation and function (Table 3 and Figure 2) [140]. Due to its energy storage role,
WAT undergoes dynamic changes which reflect the balance between energy intake and expenditure,
with excess energy intake resulting in increased lipid storage and differentiation of pre-adipocytes to
mature adipocytes [141]. Increasing data show that this differentiation of pre-adipocytes is further
characterized by changes in the miRNA expression profile of WAT, including both upregulated miRNAs
(e.g., MiR-103, MiR-107, MiR-143, MiR-26b, MiR-375, MiR-21, MiR-148a, and MiR-30) [94,142–147]
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and downregulated miRNAs (e.g., MiR-221, MiR-155, MiR-424, MiR-210, and MiR-125b) [143,148,149].
As WAT and BAT adipogenesis share common pathways, there is an overlap in the miRNAs identified
in both WAT and BAT, which mediate various effects [51,135].
Table 3. Selected key microRNAs (miRNAs) and their reported effects in white adipose tissue (WAT).
miRNA Function(s) Target(s) * Reference(s) andCorresponding Study Model(s)
MiR-181
Elevated expression in obese WAT,
promotes insulin resistance and
inflammation in WAT
PTEN, TNFA
[150]: Piglet; in vitro
[151]: Review
[152]: Human; mouse
MiR-30a
Stimulates adipogenesis, protects
adipocytes against inflammation,
prevents polarization of macrophages
to the M1 phenotype
STAT1, DLL4
[94]: In vitro
[153]: Mouse; in vitro
[113]: Human; mouse
MiR-143 Promotes adipocyte differentiationand insulin resistance
ERK5, FGF7, MAP3K7,
IGF2R, Opr8
[154]: Rat; in vitro
[155]: In vitro
[156]: Mouse; in vitro
[157]: Human; mouse, in vitro
[158]: Human; in vitro
MiR-103
Pro-adipogenic, increases lipid
accumulation, attenuates insulin
signaling and promotes apoptosis
in pre-adipocytes
RAI14,
Caveolin-1, Wnt3a
[159]: Piglet; in vitro
[160]: Human; mouse; in vitro
[161]: In vitro
MiR-107
Anti-adipogenic, attenuates insulin
signaling and promotes apoptosis
in pre-adipocytes
CDK6,
Caveolin-1, Wnt3a
[83]: In vitro
[160]: Human; mouse; in vitro
[161]: In vitro
MiR-221 Negative regulator of adipogenesis,pro-inflammatory effects ETS1, Sirt1, AdipoR1
[162]: Human; in vitro
[163]: Mouse; in vitro
MiR-17
Prevents macrophage-mediated
AT inflammation and improves
insulin resistance
Ask1, STAT3 [164]: Mouse; in vitro[165]: Mouse; in vitro
MiR-27a
Anti-adipogenic, upregulated
expression in 3T3-L1 adipocytes and
ob/ob mice, increased in the circulation
of patients with T2DM or obesity
Pparg [166]: In vitro[167]: Rat; in vitro
MiR-130
Anti-adipogenic, mediates the
inhibitory effects of TNFA on PPARG,
pro-inflammatory effects
PPARG, Apcdd1
[168]: Mouse; in vitro
[169]: Human; in vitro
[170]: Human; mouse; in vitro
MiR-33
Attenuates adipogenesis and lipid
accumulation, regulates cholesterol
efflux and HDL synthesis
HMGA2, ABCA1
[171]: Mouse; in vitro
[172]: Monkey; in vitro
[173]: Human; in vitro
MiR-369-5p Anti-adipogenic FABP4 [174]: Human; in vitro
* All abbreviations are detailed in the list of abbreviations of the manuscript.
MiR-181: The MiR-181 family is composed of six mature miRNAs (MiR-181a-1, MiR-181a-2,
MiR-181b-1, MiR-181b-2, MiR-181c, and MiR-181d) that are highly expressed in multiple tissues and are
encoded in three independent paralog precursor transcripts on three corresponding chromosomes [175].
The MiR-181 family has been identified as a non-redundant metabolic rheostat/regulator, regulating
the phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog deleted on chromosome 10
(PTEN) signaling axis [151]. Of note, MiR-181a targets TNFA and promotes adipogenesis [150].
Interestingly, gut microbiota appear to impact on the expression of the MiR-181 family in white
adipocytes in mice and, thus, is further implicated in the regulation of key pathways controlling
adiposity, insulin sensitivity, and WAT inflammation [152]. Indeed, a HFD is shown to result in altered
composition of the gut microbiome, with aberrant MiR-181 overexpression in WAT adipocytes and
development of obesity, insulin resistance, and WAT inflammation [152]. Moreover, Virtue et al. showed
that the MiR-181 family represses several critical genes in pathways controlling insulin signaling and
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WAT adipogenesis [152]. As such, this regulation of MiR-181 may serve as a rheostatic mechanism
which allows rapid and global modulation of gene expression programs in white adipocytes in response
to microbiota-derived signals [152]. Overall, these findings suggest that MiR-181 regulation in WAT
may constitute an additional potential mechanism by which the gut microbiota can control mammalian
metabolism. Thus, the MiR-181 family may represent a potential novel therapeutic target to modulate
WAT function in the context of obesity.
MiR-30a: MiR-30a is shown to directly target the signal transducer and activator of transcription 1
(STAT1) in both human and mouse cells, with MiR-30a expression in scAT protecting adipocytes
from detrimental effects of pro-inflammatory cytokines and leading to improved insulin sensitivity in
obese mice [113]. As such, MiR-30a expression in adipocytes may have an anti-inflammatory effect
mediated through direct suppression of the STAT1 signaling pathway [113]. However, STAT1 activation
inhibits MiR-30a expression in adipocytes, potentially contributing to the chronic inflammatory state
that characterizes obesity [113]. Moreover, the MiR-30 family is highly conserved [176–178] and
may play a role in modulating the polarization of macrophages in visceral AT through regulation of
Delta-like protein 4 (DLL4; a Notch1 ligand that contributes to metabolic disease and macrophage
inflammation), with downregulation of several miRNAs of the MiR-30 family (MiR-30a-5p, MiR-30c-5p,
and MiR-30e-5p) in adipose tissue macrophages in obesity [153]. Indeed, Miranda et al. showed
upregulation of DLL4 in adipose tissue macrophages in obesity, whilst MiR-30 inhibition in vitro
triggered DLL4-Notch1 signaling and pro-inflammatory responses in macrophages [153].
Furthermore, overexpression of MiR-30a-5p also decreased M1 polarization in the RAW264.7
macrophage cell line (M1 and M2 macrophage polarization contribute to pro-inflammatory and
anti-inflammatory responses, respectively), suggesting that MiR-30 is involved in attenuating M1
macrophage activation through regulation of the DLL4-Notch signaling pathway [153]. Interestingly,
a HFD appears to contribute to DNA hyper-methylation of MiR-30 genes, leading to MiR-30
downregulation and promoting inflammation and insulin resistance in obesity via increased
DLL4-Notch signaling [153]. Thus, this DNA methylation may attenuate MiR-30 expression, suggesting
important roles for miRNAs and DNA methylation in the regulation of adipose tissue macrophage
polarization and obesity-induced insulin resistance [153]. Finally, Youssef et al. have shown that
MiR-30a-5p targets genes implicated in AMPK signaling, with a HFD resulting in downregulation of
this miRNA [135].
MiR-143: MiR-143 has been identified as an important regulator of adipocyte differentiation
in both humans and mice, targeting the extracellular-signal-regulated kinase 5 (ERK5) [155,179,180].
ERKs inhibit adipogenesis in the later stages of differentiation by phosphorylating PPARG, thus MiR-143
promotes adipocyte differentiation via the ERK pathway, specifically via ERK5 [181]. MiR-143 inhibition
suppresses adipogenic marker genes (hormone-sensitive lipase, GLUT4, AP2, PPARG) and triglyceride
accumulation in scAT pre-adipocytes [155]. In human pre-adipocytes, Esau et al. showed that MiR-143
is induced during differentiation, while MiR-143 inhibition with antisense oligonucleotides blocked
this differentiation [155]. Similarly, Chen et al. reported that MiR-143 enhances the differentiation
of cultured human pre-adipocytes and directly targets FGF7, which may function as a fine-tuning
molecule in adipogenesis [154].
In addition, bioinformatic analyses have predicted that MiR-143 can target the mitogen-activated
protein kinase 7 (MAP3K7) gene, which is involved in the TGFB pathway [158]. TGFB acts via SMAD
proteins (SMAD2 and SMAD3) to inhibit the induction of transcription factors that regulate adipogenesis
(e.g., PPARG, C/EBPA and ADD1) [182,183]. As such, TGFB inhibits adipocyte differentiation,
with decreased surface expression of TGFB receptors during adipocyte differentiation [182]. Therefore,
although the exact effects of MiR-143 on this pathway are not clarified yet, MiR-143 appears to target the
TGFB pathway by reducing cell surface expression of TGFB receptors or inhibiting SMAD proteins [158].
Furthermore, FFA and leptin can significantly reduce the expression of MiR-143 in human visceral
adipocytes [184]. Since leptin has been previously found to inhibit adipogenesis [185], the findings by
Zhu et al. suggest that this can be through MiR-143 downregulation [184]. Indeed, in obesity, there is
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an increase in FFA and leptin release by WAT adipocytes that can act in an autocrine manner to further
cause adipocyte dysfunction [14].
Of note, MiR-143 may also induce insulin resistance in vascular smooth muscle cells exposed to
adipocyte-derived factors and in hepatocytes from MiR-143 transgenic mice by downregulating the
expression of oxysterol-binding protein-related protein 8 (OPR8), which impairs protein-kinase B (AKT)
activation and ultimately downstream insulin signaling [156,186]. Moreover, compared to controls,
significantly elevated MiR-143-3p levels in serum and urine have been found in patients with metabolic
syndrome, with the insulin-like growth factor 2 receptor (IGF2R) gene being among the target genes of
MiR-143-3p [157]. As such, MiR-143-3p knockdown was shown to protect against insulin resistance
in patients with metabolic syndrome via targeting of IGF2R and activation of the insulin signaling
pathway [157]. However, MiR-143-3p overexpression was shown to impair insulin-stimulated AKT
activation and glucose uptake in 3T3-L1 pre-adipocytes [157].
MiR-103 and MiR-107: MiR-103 and MiR-107 have similar nucleotide sequences, with the exception
of one nucleotide at the 3′ end [187]. Increased MiR-103 expression has been reported during adipocyte
maturation, with ectopic expression of this miRNA accelerating the expression of pro-adipogenic genes
and lipid accumulation, whereas antisense inhibition of MiR-103 reverses these effects [143,159,188,189].
Whilst investigating the effects of MiR-103 on porcine pre-adipocyte differentiation, Li et al. found that
MiR-103 inhibition resulted in increased mRNA and protein expression of retinoic acid-induced
protein 14 (RAI14) in the early stages of adipogenesis [159]. RAI14 is abundantly expressed in porcine
pre-adipocytes, with its expression declining during differentiation [159]. Therefore, MiR-103 may
target the RAI14 gene and reduce its expression, to promote adipogenesis [159]. Interestingly, retinoic
acid (a metabolite of vitamin A) is suggested to exert anti-adipogenic effects potentially through
RAI14 induction [159,190]. Furthermore, MiR-103 can promote adipogenesis through activation of the
protein kinase B/mammalian target of rapamycin signaling pathway (AKT/mTOR pathway; with an
important role in promoting adipogenesis) [191–193], resulting in enhanced Pparg expression in murine
pre-adipocytes [189]. Indeed, inhibition of MiR-103 has been shown to abolish these effects [189].
Finally, MiR-103 reverses the anti-adipogenic effects of myocyte enhancer factor 2D (MEFD2), which is
a transcription factor that negatively regulates pre-adipocyte differentiation by downregulating the
expression of multiple adipocyte markers (PPARG, C/EBPA, FABP4, and FA synthase) [189].
Unlike MiR-103, MiR-107 has been found to suppress pre-adipocyte differentiation by targeting
the cell division protein kinase 6 (CDK6) gene [83]. Attenuation of CDK6 signaling can directly reduce
the expression of pro-adipogenic genes and cause unnecessary cell cycle arrest at the G1 phase [83].
Although MiR-103 and MiR-107 have opposing effects on adipogenesis, both of these miRNAs are
increased in the liver of obese mice and are associated with endogenous glucose production and insulin
resistance [160]. Notably, caveolin-1 (Cav-1; a principle protein of caveolae in adipocytes and an
important regulator of insulin signaling) is downregulated by MiR-103 and MiR-107 in WAT and liver
tissue [160]. Silencing of these MiRNAs results in upregulation of Cav-1 expression in both tissues,
as well as decreased adipocyte size and improved insulin signaling and glucose uptake [160]. In T2DM,
increased levels of MiR-103 and MiR-107 have also been found in the circulation, suggesting that these
miRNAs can be potential T2DM biomarkers [194]. Finally, a recent study has also found that expression
of MiR-103 and MiR-107 is increased during apoptosis of murine pre-adipocytes [161]. Moreover,
it appears that MiR-103 and MiR-107 can promote endoplasmic reticulum (ER) stress-mediated
apoptosis by targeting the Wnt3a/β-catenin/activating transcription factor 6 (ATF6) signaling pathway
in pre-adipocytes [161]. As such, MiR-103 and MiR-107 could also be implicated in the increased
adipocyte apoptosis in WAT that is noted in obesity [195].
MiR-221: The expression of MiR-221 is downregulated during pre-adipocyte differentiation, whilst
it is upregulated in the WAT of patients with obesity [143,148,149]. Indeed, MiR-221 negatively regulates
adipogenesis by attenuating the induction of PPARG and C/EBPA [196]. In obesity, dysfunctional
adipocytes markedly increase the release of TNFA and leptin [197,198]. Intriguingly, Meerson et al.
found that MiR-221 expression is downregulated in response to TNFA and leptin in human
Cells 2020, 9, 2489 17 of 34
pre-adipocytes, mature adipocytes and neuroblastoma-derived cells [162]. As such, the mechanism
by which MiR-221 is upregulated in obesity is yet to be elucidated. Moreover, MiR-221 can reduce
the mRNA and protein expression of the proto-oncogene E26 transformation–specific-1 (ETS1) in
human pre-adipocytes [162]. This finding is in line with a previous study which showed that MiR-221
reduces ETS1 protein expression in endothelial cells [199]. However, TNFA and leptin increase ETS1
expression in pre-adipocytes and mature adipocytes [162], whilst ETS1 also regulates T-helper 1 (Th1)
cell inflammatory responses, angiotensinogen II-mediated endothelial inflammation and vascular
remodeling [200,201]. Thus, it has been suggested that TNFA and leptin exacerbate inflammation within
WAT by reducing MiR-221 expression which consequently increases ETS1 expression. However, Peng et
al. have reported increased MiR-221 expression after TNFA treatment in murine pre-adipocytes and that
MiR-221 inhibits Sirtuin-1 (SIRT1) protein production, resulting in increased inflammation and insulin
resistance [202]. SIRT1 protects against inflammation and TNFA induced insulin resistance, whilst
also promotes glucose uptake and insulin signaling in murine adipocytes [203]. Thus, an additional
mechanism is suggested by which TNFA contributes to WAT dysfunction via MiR-221.
Adiponectin receptor 1 (AdipoR1) is another target of MiR-221, with the latter inhibiting AdipoR1 gene
translation and attenuating its expression in pre-adipocytes, muscle and liver cells [162,163]. Adiponectin
is a well-established adipokine which regulates glucose homeostasis by promoting glucose uptake
and suppressing endogenous glucose production, whilst also improving insulin sensitivity [204–206].
These effects are induced through binding of adiponectin with its receptors (ADIPOR1 and
ADIPOR2) [207]. Of note, MiR-221 expression is downregulated during the differentiation of murine
myocytes with concomitant upregulation of AdipoR1 expression [163]. However, in mouse models of
obesity, MiR-221 expression is elevated in liver and skeletal muscle, coinciding with low ADIPOR1
protein expression [163]. These findings suggest that MiR-221 can potentially contribute to T2DM
development by impairing glucose homeostasis and insulin signaling through downregulation of
AdipoR1 expression in metabolically active tissues.
MiR-17: MiR-17 is reduced in human WAT in obesity, insulin resistance, and metabolic disease and
circulating MiR-17 is significantly lower in metabolic disease [208,209]. Notably, Zhang and colleagues
showed that MiR-17 improved inflammation-induced insulin resistance by directly suppressing the
expression of the apoptosis signal-regulating kinase 1 (Ask1) gene in macrophages [164]. ASK1 is a
member of the MAP kinase family and is involved in the regulation of macrophage activation [210].
In addition, MiR-17 indirectly increased insulin-stimulated glucose uptake by reducing the production
of pro-inflammatory cytokines [210]. Indeed, MiR-17 overexpression was shown to reduce the
secretion of pro-inflammatory cytokines (interleukin-6, interleukin-1B and TNFA) in LPS-stimulated
macrophages, whereas all these MiR-17-induced effects were reversed by Ask1 overexpression [164].
Overall, MiR-17 appears implicated in inflammatory responses [211,212], with inhibition of MiR-17-5p
further inhibiting the activation of macrophages in T2DM [213]. MiR-17-5p also blocks the expression
of STAT3 [165], which is a major regulatory pathway of macrophage activation, thereby reducing the
suppressive function of myeloid-derived suppressor cells. These studies consistently suggest that
MiR-17 may play a role in preventing macrophage-mediated AT inflammation and improve insulin
resistance, providing an additional target for T2DM treatment [164].
MiR-27a: MiR-27a is considered a crucial miRNA in WAT [140,214], which is reported to act as a
negative regulator of adipogenesis [215,216]. MiR-27a is upregulated in 3T3-L1 adipocytes and ob/ob
mice [166,167], as well as in the circulation of patients with T2DM or obesity [217]. As such, a number
of studies have identified increased MiR-27a levels in patients with obesity, compared to lean controls,
with correlations noted between serum MiR-27a and adipokine levels [149,218]. Notably, MiR-27a is
reported to impact on M2 cytokine expression [219]. Furthermore, the PPAR family is identified as a
potential target for MiR-27a [220,221], with MiR-27a upregulation having been shown to suppress the
transcription regulation and expression of Pparg [166,222]. Indeed, MiR-27a can bind to the 3′-UTR
of Pparg mRNA with a high score [222]. Moreover, Yao et al. reported increased MiR-27a serum
levels in HFD-fed mice, with increased fat percentage and adipocyte insulin resistance [223]. In this
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study, increased cytokine levels were noted with MiR-27a overexpression, whilst decreased levels
were documented with MiR-27a knockdown after 4 weeks of HFD [223]. Overall, it is suggested that
MiR-27a in WAT might represent an important target in macrophage activation and regulate local or
systematic obesity-induced insulin resistance via PPARG/nuclear factor kappa B (NFKB) [223].
MiR-130: MiR-130a and MiR-130b expression levels decline during the differentiation of human
and murine pre-adipocytes [169]. Loss and gain of function experiments revealed that MiR-130 directly
inhibits PPARG gene and protein expression, resulting in reduced triglyceride accumulation, as well
as reduced expression of adipocyte-specific genes (e.g., FABP4, lipoprotein lipase and adipsin) [169].
MiR-130 expression was downregulated in scAT of patients with obesity compared to controls, and,
accordingly, PPARG mRNA expression was upregulated [169]. An inverse correlation was also
found between MiR-130 and BMI, suggesting that MiR-130 expression decreases with increased
adiposity [169].
As aforementioned, it is well established that obesity can result in impaired adipogenesis,
which contributes to AT dysfunction [224–226]. This adipogenesis dysregulation can be attributed to
the pro-inflammatory environment of WAT in obesity, where pro-inflammatory cytokines (e.g., TNFA)
can exert anti-adipogenic effects on adipocytes through downregulation of PPARG, C/EBPA and FABP4
expression [224–226]. In this context, Kim et al. further reported that the negative effects of TNFA
on PPARG expression were mediated through MiR-130 [168]. Indeed, it has been previously shown
that TNFA downregulates PPARG via activation of NFKB [227]. These findings were confirmed by
Kim et al. who also found that activation of this pathway is responsible for TNFA-induced MiR-130
expression [168]. Of note, MiR-130b alone can also increase the accumulation of macrophages in WAT
of HFD-fed mice and can polarize macrophages to express the M1 phenotype by targeting Pparg [228].
Therefore, MiR-130b further contributes to the overall inflammatory state of WAT in obesity.
Furthermore, MiR-130 can suppress adenomatosis polyposis coli down-regulated 1 (Apcdd1),
encoding the APCDD1 protein which is an inhibitor of the Wnt signaling pathway [170]. APCDD1
mRNA and protein expression is upregulated during pre-adipocyte differentiation and, accordingly,
expression of Wnt proteins is decreased [170]. In both subcutaneous and visceral AT, diet-induced
obese mice expressed significantly higher levels of MiR-130, which corresponded to decreased APCDD1
levels and increased Wnt3a levels [170], resulting in reduced adipogenesis in these tissues. Compared
to controls, reduced expression levels of APCDD1 and adipogenic markers (PPARG and C/EBPA)
were also observed in scAT of patients with obesity [170]. Interestingly, both genetic and diet-induced
mouse models of obesity have increased circulating MiR-130 levels and increased MiR-130 expression
in WAT [168,229].
Similarly, several studies have reported increased circulating levels of MiR-130b in individuals
with obesity, which positively correlated with metabolic parameters, including BMI, insulin resistance
and triglyceride levels [229–231]. In accordance with this, Wang et al. found that TGFB, which is
increased in the AT of obese mice and has well-known anti-adipogenic effects [232,233], can increase
MiR-130b secretion via neutral sphingomyelinase 2 [227]. This effect can potentially explain the
increased circulating MiR-130b levels observed in obesity. Similarly, Ortega and colleagues reported
decreased circulating MiR-130b levels in T2DM patients with and without obesity [234] as well as
decreased expression of MiR-130b in scWAT of patients with obesity (with or without coexisting
T2DM) [148]. A more recent study measuring MiR-130 (a/b) serum levels in patients with coronary
artery disease (CAD) with and without T2DM showed significantly decreased circulating MiR-130 levels
in non-diabetic patients with CAD and even more decreased in patients with CAD and T2DM [235].
The metabolic dysregulation that is associated with T2DM may explain, at least partly, why patients
with T2DM express lower circulating MiR-130 levels compared to patients with only obesity.
MiR-33: MiR-33a and MiR-33b, which belong to the MiR-33 family, are found in the introns of genes
encoding sterol regulatory element-binding proteins (SREBPs); SREBP2 and SREBP1, respectively [236].
These proteins are involved in the synthesis of fatty acids and cholesterol, as well as cholesterol
uptake [236]. Although MiR-33b is upregulated during adipogenesis, this miRNA has been reported
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to negatively regulate porcine and human pre-adipocyte differentiation [173,237]. Overexpression of
MiR-33b can attenuate lipid accumulation and downregulate adipogenic markers such as PPARG,
C/EBPA, GLUT4, and adiponectin [237]. Furthermore, MiR-33b can decrease mRNA and protein
expression of HMGA2 [173]. HMGA2 is a transcription factor that is upregulated in the early stages of
differentiation and, together with STAT3, regulates pre-adipocyte proliferation and differentiation [238,239].
Silencing of this transcription factor has similar effects to overexpression of MiR-33, attenuating
adipogenesis [173].
A well-studied target of MiR-33 is the gene encoding the adenosine triphosphate–binding cassette
transporter (ABCA1), which regulates cholesterol efflux and HDL synthesis, with these processes
being attenuated by MiR-33 [171,172]. Of note, genetic ablation of MiR-33 in mice (MiR-33−/−) leads
to increased body weight, elevated levels of circulating cholesterol, impaired glucose metabolism,
and hepatosteatosis [240]. In addition, MiR-33 knockdown has been shown to increase macrophage
accumulation within WAT and, hence, augment inflammation [240]. The expression of key enzymes
involved in lipolysis was also downregulated in WAT, contributing to impaired FFA release in response
to lipolytic stimuli (e.g., insulin) [241]. Moreover, Hmga2 expression was significantly higher in
MiR-33−/− mice, thus promoting WAT expansion and increased cellular lipid accumulation [241].
However, pharmacological inhibition of MiR-33 is being considered for preventing atherosclerosis,
with MiR-33 inhibitors promoting fatty acid oxidation and improving the lipidemic profile (decreased
triglycerides and increased HDL levels) [172]. Contrary to genetically silencing MiR-33, MiR-33
inhibition can promote M2 macrophage polarization in AT [242]. Notably, Karunakaran et al. further
reported that MiR-33 inhibitors did not affect any other metabolic factors that were associated with
HFD in mice, suggesting that this pharmacological inhibition may be effective and safe in treating
atherosclerosis [242].
MiR-369-5p: MiR-369-5p appears to negatively regulate adipogenesis [174], directly targeting
FABP4 (FABP4 is responsible for the transportation of fatty acids to different parts of the cell and
their storage as lipid droplets) [243]. Ectopic expression of MiR-369-5p results in downregulation
of the FABP4 gene expression without affecting the expression of PPARG, which is a regulator of
FABP4 [174,243]. To date, the role of MiR-396-5p in regulating WAT has not been extensively studied
and, thus, further research is required to clarify its exact role in WAT.
6. Conclusions
Obesity is a worldwide epidemic, posing a significant disease burden with a still unmet need for
novel effective therapies. A number of miRNAs have been identified to play key regulatory roles in
BAT, brite AT and WAT by acting on transcription factors to promote or inhibit adipocyte differentiation,
thus regulating key signaling pathways of adipogenesis. Our understanding of such miRNA-induced
effects in AT is rapidly growing, in parallel to advances in AT biology and the recent heightened attention
on the role of both BAT and browning of WAT in humans. In this context, an increasing number of
AT-related miRNAs have been identified as biomarkers and potential therapeutic targets for obesity and
obesity-related cardio-metabolic diseases. For example, since MiR-103 and MiR-107 have been shown to
regulate insulin resistance and that antagomiR-mediated MiR-103/107 silencing significantly improves
insulin sensitivity and glucose tolerance in obese mice [160], anti-miR-103/107 oligonucleotides
(anti-miRs) are explored for the treatment of T2DM and NAFLD (e.g., phase I/IIA randomized clinical
trial of antagomiR-103 and -107 in subjects with T2DM and NAFLD; ClinicalTrials.gov: NCT02826525).
However, the clinical applicability of such novel miRNA-based therapies requires additional trials,
which will address their efficacy, as well as potential interactions and safety concerns [244,245]. Overall,
it is evident that further rigorous research is required in this field to exploit the full potential of the
burgeoning diagnostic and therapeutic implications of these novel regulators of AT differentiation
and function.
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Abbreviations
3′ UTR 3′ untranslated regions
ABCA1 Adenosine triphosphate–binding cassette transporter
ADAM A disintegrin and metalloprotease domain
ADAM17 ADAM metallopeptidase domain 17
ADIPOQ Adiponectin gene
AdipoR1 Adiponectin receptor 1
AKT Protein-kinase B
AMPKα1 AMP-activated protein kinase alpha1
AP2 Adipocyte protein 2
APCDD1 Adenomatosis polyposis coli downregulated 1
ASK1 Apoptosis signal-regulating kinase 1
AT Adipose tissue
ATF2 Activating transcription factor 2
ATF6 Activating transcription factor 6
ATG7 Autophagy-related gene 7
ATP Adenosine triphosphate
Bace1 Beta-site amyloid precursor protein cleaving enzyme 1
BAT Brown adipose tissue
BMI Body mass index
BMP7 Bone morphogenetic protein 7
C/EBP CCAAT/enhancer-binding protein
CAD Coronary artery disease
cAMP Cyclic adenosine 3′,5′-monophosphate
Cav-1 Caveolin-1
Cdc34 Cell division cycle 34
CDK6 Cell division protein kinase 6
CIDEA Cell death-inducing DNA fragmentation factor-like effector A
Creb cAMP-response element binding protein
CVD Cardiovascular disease
DGCR8 DiGeorge syndrome critical region 8
DLL4 Delta-like protein 4
E2f6 E2F transcription factor 6
EBF2 Early B-cell factor transcription factor 2
Egr1 Early growth factor response 1
EHMT1 Euchromatic Histone Lysine Methyltransferase 1
ER Endoplasmic reticulum
ERK Extracellular-signal-regulated kinase
ETS1 E26 transformation–specific-1
FABP4 Fatty acid-binding protein 4
Fbxl19 F-box and leucine rich repeat protein 19
FFA Free fatty acids
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FFAR4 Free fatty acid receptor 4
FGF7 Fibroblast growth factor 7
FGFR1 Fibroblast growth factor receptor 1
FNDC5 Fibronectin type III domain containing 5
GLUT4 Glucose Transporter Type 4
HDAC3 Histone deacetylase 3
HFD High-fat diet
HIF1an Hypoxia inducible factor 1 subunit alpha inhibitor
hMADS Human multipotent adipose-derived stem
HMGA2 High-mobility group AT-hook 2
HOX Homeobox
HOXC8 Homeobox C8
IgF2 Insulin like growth factor 2
Igf2bp1 Insulin-like growth factor 2 mRNA-binding protein 1
IGF2R Insulin-like growth factor 2 receptor
Insig1 Insulin-induced gene 1
IR Insulin resistance
IRS-1 Insulin receptor substrate 1
MAP3K7 Mitogen-activated protein kinase kinase kinase 7
MAPK Mitogen-activated protein kinase
Mef2 Myocyte enhancer factor-2
MMP11 Matrix metalloproteinase 11
MiR- MicroRNA
miRNA MicroRNA
mRNA Messenger RNA
MYF5+ Myogenic factor 5 positive cells
NAD+ Nicotinamide adenine dinucleotide
NAFLD Non-alcoholic fatty liver disease
NFKB Nuclear factor kappa B
OPR8 Oxysterol-binding protein-related protein 8
Pde1b Phosphodiesterase 1b
Pdgfr2 Platelet-derived growth factor receptor 2
PGC1A Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
PGC1B Peroxisome proliferator-activated receptor gamma, coactivator 1-beta
PI3K Phosphatidylinositol 3-kinase
PKA Protein kinase cAMP dependent
PNPLA2 Patatin-like phospholipase domain-containing protein 2
PPAR Peroxisome proliferator-activated receptor
PRDM16 PR domain-containing protein 16
pri-miRNA Primary miRNA
PTEN Phosphatase and tensin homolog deleted on chromosome 10
RAI14 Retinoic acid-induced protein 14
RIP140 Receptor-interacting protein 140
RISC RNA-induced silencing complex
RUNX1t1 Runt-related transcription factor 1; translocated to, 1
SCF Skp–Cullin–F-box-containing
Sc Subcutaneous
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ScAT Subcutaneous adipose tissue
SIRT1 Sirtuin-1
SNS Sympathetic nervous system
SREBPs Sterol regulatory element-binding proteins
STAT1 Signal transducer and activator of transcription 1
SVF Stromal vascular fraction
T2DM Type 2 diabetes mellitus
TBX1 T-Box Transcription Factor 1
TGFB Transforming growth factor-beta
TgfBr3 Type III transforming growth factor-β receptor
Th1 T-helper 1
TMEM26 Transmembrane protein 26
TNFRSF9 Tumour necrosis factor receptor superfamily member 9
TNFA Tumour necrosis factor alpha
TOB1 Transducer of erbB-2 1
UCP1 Uncoupling protein 1
WAT White adipose tissue
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